Q2 EPS Estimates for Tourmaline Bio Decreased by Analyst

Tourmaline Bio, Inc. (NASDAQ:TRML - Free Report) - Stock analysts at HC Wainwright lowered their Q2 2025 EPS estimates for shares of Tourmaline Bio in a report issued on Monday, May 5th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings per share of ($0.91) for the quarter, down from their previous estimate of ($0.86). HC Wainwright has a "Buy" rating and a $50.00 price objective on the stock. The consensus estimate for Tourmaline Bio's current full-year earnings is ($3.02) per share. HC Wainwright also issued estimates for Tourmaline Bio's Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.92) EPS, FY2025 earnings at ($3.64) EPS, Q1 2026 earnings at ($0.93) EPS, Q3 2026 earnings at ($0.95) EPS and Q4 2026 earnings at ($0.96) EPS.

TRML has been the topic of a number of other research reports. Chardan Capital reaffirmed a "buy" rating and set a $70.00 price objective on shares of Tourmaline Bio in a research note on Monday. Wedbush raised their price target on shares of Tourmaline Bio from $42.00 to $43.00 and gave the company an "outperform" rating in a report on Friday, March 14th. Finally, Lifesci Capital assumed coverage on shares of Tourmaline Bio in a report on Monday, February 24th. They issued an "outperform" rating and a $58.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $49.33.

Tourmaline Bio Stock Performance

Tourmaline Bio stock opened at $14.54 on Wednesday. Tourmaline Bio has a fifty-two week low of $11.56 and a fifty-two week high of $29.79. The company has a market capitalization of $373.46 million, a price-to-earnings ratio of -5.16 and a beta of 2.11. The stock has a fifty day moving average of $15.32 and a two-hundred day moving average of $18.98.

Tourmaline Bio (NASDAQ:TRML - Get Free Report) last issued its quarterly earnings data on Friday, May 2nd. The company reported ($0.89) earnings per share for the quarter, topping analysts' consensus estimates of ($0.91) by $0.02.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Barclays PLC lifted its position in shares of Tourmaline Bio by 283.7% during the third quarter. Barclays PLC now owns 31,833 shares of the company's stock worth $819,000 after purchasing an additional 23,536 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Tourmaline Bio by 16.5% during the third quarter. JPMorgan Chase & Co. now owns 14,804 shares of the company's stock valued at $381,000 after buying an additional 2,100 shares in the last quarter. Brooklyn Investment Group bought a new position in Tourmaline Bio during the 4th quarter worth approximately $32,000. SG Americas Securities LLC lifted its holdings in Tourmaline Bio by 3.4% during the 4th quarter. SG Americas Securities LLC now owns 34,812 shares of the company's stock worth $706,000 after buying an additional 1,140 shares during the last quarter. Finally, Rhumbline Advisers grew its position in shares of Tourmaline Bio by 2.1% in the 4th quarter. Rhumbline Advisers now owns 35,591 shares of the company's stock worth $722,000 after acquiring an additional 718 shares in the last quarter. 91.89% of the stock is owned by institutional investors and hedge funds.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.